The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis

Abstract

Background Haemophilia A (HA) has been associated with poor health-related quality of life and a large economic burden, accentuated by severity, arthropathy, and inhibitors. To meet global standards of care, the management of HA should align with the principles of care outlined by the World Federation of Haemophilia. The aims of the present study were to establish a set of proposals to improve HA management within the Spanish National Health System (SNHS) and to estimate the impact its hypothetical implementation would generate from a clinical, healthcare, economic, and social perspective. Methods A multidisciplinary group of experts agreed on a set of 15 proposals to improve HA management within the SNHS. Thereafter, a forecast-type Social Return on Investment analysis was carried out to estimate the impact of implementing this set of proposals within the SNHS over a one-year timeframe, in relation to the required investment. Results This study estimated that the implementation of the complete set of 15 proposals would require a total investment of 2.34 M€ and have a total impact of 14.60 M€. Accordingly, every euro invested in the complete set of 15 proposals would yield a social return of €6.23 (€3.37 in the worst-case scenario and €9.69 in the best-case scenario) of both tangible and intangible nature in similar proportions (45.71 and 54.29%, respectively). Conclusions These results can be used to inform policy and practice such that interventions that may potentially improve current public health challenges associated with the management of HA may be implemented.

A Social Return on Investment Analysis of Improving the Management of Chronic Obstructive Pulmonary Disease Within the Spanish National Healthcare System

“… 19 Despite the subjectivity associated with some of these methods, valuing intangible aspects without a market price is essential to expose social returns, usually associated with patient and caregiver needs, which would otherwise remain unaccounted for. Previous experiences have been used to guide decisions relative to healthcare interventions, 18 , 20–23 including interventions on chronic diseases overall, 24 heart failure, 25 psoriasis, 26 multiple sclerosis, 27 rheumatoid arthritis, 28 or haemophilia A, 29 among others. To date, no other study has used the SROI method to assess the impact of any healthcare intervention specifically designed for COPD.…”

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

“…The SROI method has been previously used in the area of oncology (de Castro Carpeño et al, 2018; Laing & Moules, 2016) and other health‐related areas such as pulmonology (Merino, Lorenzo, et al, 2022), haematology (Soto et al, 2022), cardiology (Merino et al, 2020; Piñeiro et al, 2015), nephrology (Lophongpanit et al, 2019), neurology (Jones et al, 2014; Moral Torres et al, 2020; Willis et al, 2018), dermatology (Carretero et al, 2020), rheumatology (Merino, Ivanova, et al, 2022), ageing (Jones et al, 2015; Scharlach, 2015) or maternity (Banke‐Thomas et al, 2017; Goudet et al, 2018), among others (Banke‐Thomas et al, 2015; Masters et al, 2017). However, we are unaware of any study on the impact of MM management using the SROI method.…”